Do analysts recommend NUWE or DYNT?

Given Dynatronics' higher probable upside, analysts plainly believe Dynatronics is more favorable than Nuwellis. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuwellis 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Dynatronics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better valuation and earnings, NUWE or DYNT?

Dynatronics has higher revenue and earnings than Nuwellis. Nuwellis is trading at a lower price-to-earnings ratio than Dynatronics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nuwellis $8.27M 0.03 -$17.52M -$2.24 thousand N/A Dynatronics $33.60M 0.00 -$2.70M -$1.35 N/A

Is NUWE or DYNT more profitable?

Dynatronics has a net margin of -8.35% compared to Nuwellis' net margin of -214.90%. Dynatronics' return on equity of -41.81% beat Nuwellis' return on equity. Company Net Margins Return on Equity Return on Assets Nuwellis -214.90% -32,351.83% -249.08% Dynatronics -8.35% -41.81% -9.56%

Do analysts recommend NUWE or SSKN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuwellis 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Strata Skin Sciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation and earnings, NUWE or SSKN?

Strata Skin Sciences has higher revenue and earnings than Nuwellis. Strata Skin Sciences is trading at a lower price-to-earnings ratio than Nuwellis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nuwellis $8.27M 0.03 -$17.52M -$2.24 thousand N/A Strata Skin Sciences $30.98M 0.02 -$10.09M -$1.41 N/A

Is NUWE or SSKN more profitable?

Strata Skin Sciences has a net margin of -35.64% compared to Nuwellis' net margin of -214.90%. Strata Skin Sciences' return on equity of -476.73% beat Nuwellis' return on equity. Company Net Margins Return on Equity Return on Assets Nuwellis -214.90% -32,351.83% -249.08% Strata Skin Sciences -35.64% -476.73% -33.49%

Do analysts rate BIOL or NUWE?

Given BIOLASE's higher probable upside, analysts clearly believe BIOLASE is more favorable than Nuwellis. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BIOLASE 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Nuwellis 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation & earnings, BIOL or NUWE?

Nuwellis has lower revenue, but higher earnings than BIOLASE. Nuwellis is trading at a lower price-to-earnings ratio than BIOLASE, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BIOLASE $48.83M 0.00 -$20.63M -$14.94 N/A Nuwellis $8.27M 0.03 -$17.52M -$2.24 thousand N/A

Is BIOL or NUWE more profitable?

BIOLASE has a net margin of -41.65% compared to Nuwellis' net margin of -214.90%. BIOLASE's return on equity of -1,782.73% beat Nuwellis' return on equity. Company Net Margins Return on Equity Return on Assets BIOLASE -41.65% -1,782.73% -55.31% Nuwellis -214.90% -32,351.83% -249.08%

Do analysts recommend PFSA or NUWE?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Profusa 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Nuwellis 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation & earnings, PFSA or NUWE?

Nuwellis has higher revenue and earnings than Profusa. Nuwellis is trading at a lower price-to-earnings ratio than Profusa, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Profusa $100K 4.36 -$35.82M -$169.72 N/A Nuwellis $8.27M 0.03 -$17.52M -$2.24 thousand N/A

Is PFSA or NUWE more profitable?

Profusa has a net margin of 0.00% compared to Nuwellis' net margin of -214.90%. Profusa's return on equity of 0.00% beat Nuwellis' return on equity. Company Net Margins Return on Equity Return on Assets Profusa N/A N/A -1,348.07% Nuwellis -214.90% -32,351.83% -249.08%

Does the media refer more to PFSA or NUWE?

In the previous week, Profusa had 3 more articles in the media than Nuwellis. MarketBeat recorded 4 mentions for Profusa and 1 mentions for Nuwellis. Profusa's average media sentiment score of 0.15 beat Nuwellis' score of 0.00 indicating that Profusa is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Profusa 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Nuwellis 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer XAGE or NUWE?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Longevity Health 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Nuwellis 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is XAGE or NUWE more profitable?

Nuwellis has a net margin of -214.90% compared to Longevity Health's net margin of -682.67%. Longevity Health's return on equity of 0.00% beat Nuwellis' return on equity. Company Net Margins Return on Equity Return on Assets Longevity Health -682.67% N/A -261.90% Nuwellis -214.90% -32,351.83% -249.08%

Nuwellis (NUWE) Competitors

$3.15 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$3.12 -0.02 (-0.79%)

As of 07/2/2026 07:59 PM Eastern

Compare

NUWE vs. DYNT, SSKN, BIOL, PFSA, and XAGE

Should you buy Nuwellis stock or one of its competitors? MarketBeat compares Nuwellis with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Nuwellis include Dynatronics (DYNT), Strata Skin Sciences (SSKN), BIOLASE (BIOL), Profusa (PFSA), and Longevity Health (XAGE). These companies are all part of the "medical equipment" industry.

How does Nuwellis compare to Dynatronics?

Nuwellis (NASDAQ:NUWE) and Dynatronics (NASDAQ:DYNT) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, valuation, dividends, profitability and analyst recommendations.

Nuwellis has a beta of 0.29, meaning that its stock price is 71% less volatile than the broader market. Comparatively, Dynatronics has a beta of 0.31, meaning that its stock price is 69% less volatile than the broader market.

In the previous week, Nuwellis had 1 more articles in the media than Dynatronics. MarketBeat recorded 1 mentions for Nuwellis and 0 mentions for Dynatronics. Nuwellis' average media sentiment score of 0.00 equaled Dynatronics'average media sentiment score.

Company	Overall Sentiment
Nuwellis	Neutral
Dynatronics	Neutral

3.1% of Nuwellis shares are owned by institutional investors. Comparatively, 4.2% of Dynatronics shares are owned by institutional investors. 1.6% of Nuwellis shares are owned by insiders. Comparatively, 2.9% of Dynatronics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Dynatronics has a net margin of -8.35% compared to Nuwellis' net margin of -214.90%. Dynatronics' return on equity of -41.81% beat Nuwellis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuwellis	-214.90%	-32,351.83%	-249.08%
Dynatronics	-8.35%	-41.81%	-9.56%

Given Dynatronics' higher probable upside, analysts plainly believe Dynatronics is more favorable than Nuwellis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuwellis	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Dynatronics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Dynatronics has higher revenue and earnings than Nuwellis. Nuwellis is trading at a lower price-to-earnings ratio than Dynatronics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuwellis	$8.27M	0.03	-$17.52M	-$2.24 thousand	N/A
Dynatronics	$33.60M	0.00	-$2.70M	-$1.35	N/A

Summary

Dynatronics beats Nuwellis on 10 of the 13 factors compared between the two stocks.

How does Nuwellis compare to Strata Skin Sciences?

Nuwellis (NASDAQ:NUWE) and Strata Skin Sciences (NASDAQ:SSKN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations, media sentiment and institutional ownership.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuwellis	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Strata Skin Sciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

3.1% of Nuwellis shares are held by institutional investors. Comparatively, 32.4% of Strata Skin Sciences shares are held by institutional investors. 1.6% of Nuwellis shares are held by insiders. Comparatively, 40.9% of Strata Skin Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Nuwellis has a beta of 0.29, meaning that its share price is 71% less volatile than the broader market. Comparatively, Strata Skin Sciences has a beta of -0.05, meaning that its share price is 105% less volatile than the broader market.

In the previous week, Nuwellis had 1 more articles in the media than Strata Skin Sciences. MarketBeat recorded 1 mentions for Nuwellis and 0 mentions for Strata Skin Sciences. Nuwellis' average media sentiment score of 0.00 equaled Strata Skin Sciences'average media sentiment score.

Company	Overall Sentiment
Nuwellis	Neutral
Strata Skin Sciences	Neutral

Strata Skin Sciences has a net margin of -35.64% compared to Nuwellis' net margin of -214.90%. Strata Skin Sciences' return on equity of -476.73% beat Nuwellis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuwellis	-214.90%	-32,351.83%	-249.08%
Strata Skin Sciences	-35.64%	-476.73%	-33.49%

Strata Skin Sciences has higher revenue and earnings than Nuwellis. Strata Skin Sciences is trading at a lower price-to-earnings ratio than Nuwellis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuwellis	$8.27M	0.03	-$17.52M	-$2.24 thousand	N/A
Strata Skin Sciences	$30.98M	0.02	-$10.09M	-$1.41	N/A

Summary

Strata Skin Sciences beats Nuwellis on 8 of the 12 factors compared between the two stocks.

How does Nuwellis compare to BIOLASE?

BIOLASE (NASDAQ:BIOL) and Nuwellis (NASDAQ:NUWE) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, valuation, earnings and dividends.

Given BIOLASE's higher probable upside, analysts clearly believe BIOLASE is more favorable than Nuwellis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BIOLASE	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Nuwellis	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Nuwellis has lower revenue, but higher earnings than BIOLASE. Nuwellis is trading at a lower price-to-earnings ratio than BIOLASE, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BIOLASE	$48.83M	0.00	-$20.63M	-$14.94	N/A
Nuwellis	$8.27M	0.03	-$17.52M	-$2.24 thousand	N/A

In the previous week, Nuwellis had 1 more articles in the media than BIOLASE. MarketBeat recorded 1 mentions for Nuwellis and 0 mentions for BIOLASE. BIOLASE's average media sentiment score of 0.00 equaled Nuwellis'average media sentiment score.

Company	Overall Sentiment
BIOLASE	Neutral
Nuwellis	Neutral

8.8% of BIOLASE shares are held by institutional investors. Comparatively, 3.1% of Nuwellis shares are held by institutional investors. 0.3% of BIOLASE shares are held by insiders. Comparatively, 1.6% of Nuwellis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

BIOLASE has a beta of 0.67, meaning that its share price is 33% less volatile than the broader market. Comparatively, Nuwellis has a beta of 0.29, meaning that its share price is 71% less volatile than the broader market.

BIOLASE has a net margin of -41.65% compared to Nuwellis' net margin of -214.90%. BIOLASE's return on equity of -1,782.73% beat Nuwellis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BIOLASE	-41.65%	-1,782.73%	-55.31%
Nuwellis	-214.90%	-32,351.83%	-249.08%

Summary

BIOLASE beats Nuwellis on 9 of the 13 factors compared between the two stocks.

How does Nuwellis compare to Profusa?

Profusa (NASDAQ:PFSA) and Nuwellis (NASDAQ:NUWE) are both small-cap medical equipment companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, earnings, analyst recommendations, valuation, media sentiment and institutional ownership.

Profusa has a beta of 0.46, meaning that its stock price is 54% less volatile than the broader market. Comparatively, Nuwellis has a beta of 0.29, meaning that its stock price is 71% less volatile than the broader market.

In the previous week, Profusa had 3 more articles in the media than Nuwellis. MarketBeat recorded 4 mentions for Profusa and 1 mentions for Nuwellis. Profusa's average media sentiment score of 0.15 beat Nuwellis' score of 0.00 indicating that Profusa is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Profusa	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nuwellis	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Profusa has a net margin of 0.00% compared to Nuwellis' net margin of -214.90%. Profusa's return on equity of 0.00% beat Nuwellis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Profusa	N/A	N/A	-1,348.07%
Nuwellis	-214.90%	-32,351.83%	-249.08%

9.8% of Profusa shares are held by institutional investors. Comparatively, 3.1% of Nuwellis shares are held by institutional investors. 0.8% of Profusa shares are held by insiders. Comparatively, 1.6% of Nuwellis shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Nuwellis has higher revenue and earnings than Profusa. Nuwellis is trading at a lower price-to-earnings ratio than Profusa, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Profusa	$100K	4.36	-$35.82M	-$169.72	N/A
Nuwellis	$8.27M	0.03	-$17.52M	-$2.24 thousand	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Profusa	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Nuwellis	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Profusa beats Nuwellis on 9 of the 13 factors compared between the two stocks.

How does Nuwellis compare to Longevity Health?

Longevity Health (NASDAQ:XAGE) and Nuwellis (NASDAQ:NUWE) are both small-cap medical equipment companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, media sentiment, valuation, risk and analyst recommendations.

Longevity Health has a beta of 0.39, indicating that its share price is 61% less volatile than the broader market. Comparatively, Nuwellis has a beta of 0.29, indicating that its share price is 71% less volatile than the broader market.

In the previous week, Nuwellis had 1 more articles in the media than Longevity Health. MarketBeat recorded 1 mentions for Nuwellis and 0 mentions for Longevity Health. Longevity Health's average media sentiment score of 0.00 equaled Nuwellis'average media sentiment score.

Company	Overall Sentiment
Longevity Health	Neutral
Nuwellis	Neutral

24.2% of Longevity Health shares are held by institutional investors. Comparatively, 3.1% of Nuwellis shares are held by institutional investors. 29.0% of Longevity Health shares are held by insiders. Comparatively, 1.6% of Nuwellis shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Nuwellis has a net margin of -214.90% compared to Longevity Health's net margin of -682.67%. Longevity Health's return on equity of 0.00% beat Nuwellis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Longevity Health	-682.67%	N/A	-261.90%
Nuwellis	-214.90%	-32,351.83%	-249.08%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Longevity Health	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Nuwellis	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Longevity Health has higher earnings, but lower revenue than Nuwellis. Longevity Health is trading at a lower price-to-earnings ratio than Nuwellis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Longevity Health	$1.05M	0.44	-$10.37M	-$4.29	N/A
Nuwellis	$8.27M	0.03	-$17.52M	-$2.24 thousand	N/A

Summary

Longevity Health beats Nuwellis on 7 of the 13 factors compared between the two stocks.

Get Nuwellis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NUWE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NUWE vs. The Competition

Export

Metric	Nuwellis	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$240K	$7.57B	$7.16B	$12.48B
Dividend Yield	N/A	1.32%	2.66%	6.52%
P/E Ratio	0.00	52.12	28.02	24.70
Price / Sales	0.03	49.46	540.37	99.49
Price / Cash	N/A	26.72	49.26	57.09
Price / Book	0.06	7.48	10.96	6.46
Net Income	-$17.52M	$159.19M	$3.57B	$337.01M
7 Day Performance	-4.55%	-0.39%	2.12%	1.69%
1 Month Performance	-46.17%	-0.43%	5.25%	3.81%
1 Year Performance	-98.91%	3.14%	33.29%	23.90%

Nuwellis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NUWE Nuwellis	0.4848 of 5 stars	$3.15 flat	N/A	-98.9%	$240K	$8.27M	N/A	70
DYNT Dynatronics	N/A	N/A	N/A	N/A	$653K	$33.60M	N/A	200
SSKN Strata Skin Sciences	N/A	$0.10 flat	N/A	-94.5%	$589K	$30.98M	N/A	120	Gap Up
BIOL BIOLASE	N/A	N/A	N/A	N/A	$581K	$48.83M	N/A	160	Positive News
PFSA Profusa	0.821 of 5 stars	$0.13 +11.6%	N/A	N/A	$540K	$100K	N/A	2	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NUWE) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nuwellis (NUWE) Competitors

NUWE vs. DYNT, SSKN, BIOL, PFSA, and XAGE

How does Nuwellis compare to Dynatronics?

Summary

How does Nuwellis compare to Strata Skin Sciences?

Summary

How does Nuwellis compare to BIOLASE?

Summary

How does Nuwellis compare to Profusa?

Summary

How does Nuwellis compare to Longevity Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NUWE vs. The Competition

Nuwellis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nuwellis (NUWE) Competitors

NUWE vs. DYNT, SSKN, BIOL, PFSA, and XAGE

How does Nuwellis compare to Dynatronics?

Which has more volatility and risk, NUWE or DYNT?

Does the media favor NUWE or DYNT?

Do institutionals & insiders believe in NUWE or DYNT?

Is NUWE or DYNT more profitable?

Do analysts recommend NUWE or DYNT?

Which has better valuation and earnings, NUWE or DYNT?

Summary

How does Nuwellis compare to Strata Skin Sciences?

Do analysts recommend NUWE or SSKN?

Do institutionals and insiders hold more shares of NUWE or SSKN?

Which has more volatility & risk, NUWE or SSKN?

Does the media refer more to NUWE or SSKN?

Is NUWE or SSKN more profitable?

Which has preferable valuation and earnings, NUWE or SSKN?

Summary

How does Nuwellis compare to BIOLASE?

Do analysts rate BIOL or NUWE?

Which has higher valuation & earnings, BIOL or NUWE?

Does the media prefer BIOL or NUWE?

Do institutionals & insiders have more ownership in BIOL or NUWE?

Which has more volatility & risk, BIOL or NUWE?

Is BIOL or NUWE more profitable?

Summary

How does Nuwellis compare to Profusa?

Which has more risk & volatility, PFSA or NUWE?

Does the media refer more to PFSA or NUWE?

Is PFSA or NUWE more profitable?

Do insiders & institutionals hold more shares of PFSA or NUWE?

Which has better valuation & earnings, PFSA or NUWE?

Do analysts recommend PFSA or NUWE?

Summary

How does Nuwellis compare to Longevity Health?

Which has more risk and volatility, XAGE or NUWE?

Does the media prefer XAGE or NUWE?

Do institutionals & insiders have more ownership in XAGE or NUWE?

Is XAGE or NUWE more profitable?

Do analysts prefer XAGE or NUWE?

Which has higher earnings & valuation, XAGE or NUWE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NUWE vs. The Competition

Nuwellis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools